| NCT04283747 |
Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04283747 |
Recruiting |
Mazandaran University of Medical Sciences |
2022-10-31 |
| NCT02301572 |
Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course |
https://ClinicalTrials.gov/show/NCT02301572 |
Completed |
Weill Medical College of Cornell University |
2016-07-31 |
| NCT03662347 |
Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP) |
https://ClinicalTrials.gov/show/NCT03662347 |
Recruiting |
Central Hospital, Nancy, France |
2022-03-31 |
| NCT03408093 |
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b |
https://ClinicalTrials.gov/show/NCT03408093 |
Completed |
Bayer |
2010-03-30 |
| NCT03401307 |
Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03401307 |
Active, not recruiting |
University of Southern Denmark |
2020-07-31 |
| NCT03396822 |
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03396822 |
Recruiting |
University of Maryland, Baltimore |
2020-09-30 |
| NCT03368677 |
Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression |
https://ClinicalTrials.gov/show/NCT03368677 |
Recruiting |
Turku University Hospital |
2022-11-30 |
| NCT03368157 |
PREG-MS: New England MS Pregnancy Registry |
https://ClinicalTrials.gov/show/NCT03368157 |
Recruiting |
Brigham and Women’s Hospital |
2019-04-07 |
| NCT03975413 |
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03975413 |
Active, not recruiting |
Rush University Medical Center |
2020-04-01 |
| NCT03826095 |
Respiratory Functions, Trunk Control and Mobility Evaluation in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03826095 |
Completed |
Hacettepe University |
2019-07-26 |
| NCT03825055 |
Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03825055 |
Recruiting |
Universita di Verona |
2022-03-31 |
| NCT03313843 |
Study to Assess OCT: RNFL and GCL in MS Patients |
https://ClinicalTrials.gov/show/NCT03313843 |
Recruiting |
Tampa Bay Uveitis Center, LLC |
2022-12-31 |
| NCT03302442 |
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03302442 |
Completed |
Nantes University Hospital |
2017-08-01 |
| NCT03291756 |
Corrona Multiple Sclerosis (MS) Registry |
https://ClinicalTrials.gov/show/NCT03291756 |
Enrolling by invitation |
Corrona, LLC. |
2100-12-31 |
| NCT03284970 |
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes |
https://ClinicalTrials.gov/show/NCT03284970 |
Completed |
EMD Serono |
2018-05-11 |
| NCT03281330 |
Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS) |
https://ClinicalTrials.gov/show/NCT03281330 |
Completed |
Hasselt University |
2018-05-30 |
| NCT03268096 |
Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination |
https://ClinicalTrials.gov/show/NCT03268096 |
Recruiting |
Fondation Ophtalmologique Adolphe de Rothschild |
2020-12-31 |
| NCT03255460 |
The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03255460 |
Completed |
Gazi University |
2018-07-04 |
| NCT03250169 |
Neurofilaments for NEDA Assessing in MS |
https://ClinicalTrials.gov/show/NCT03250169 |
Recruiting |
Queen Mary University of London |
2020-07-01 |
| NCT03217396 |
Biomarkers of Synaptic Damage in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03217396 |
Recruiting |
Neuromed IRCCS |
2020-09-01 |
| NCT03216915 |
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03216915 |
Recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2019-12-31 |
| NCT03209479 |
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) “Prevention of Relapse of Multiple Sclerosis” |
https://ClinicalTrials.gov/show/NCT03209479 |
Recruiting |
Takeda |
2025-03-31 |
| NCT03205280 |
Clinical Decision Support System (CADIMS) for MS Diagnostic |
https://ClinicalTrials.gov/show/NCT03205280 |
Recruiting |
Rennes University Hospital |
2020-03-01 |
| NCT03204747 |
Effect of Need to Void on Gait Speed in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03204747 |
Completed |
Pierre and Marie Curie University |
2017-08-31 |
| NCT03191669 |
Vaccine Exposure in Patients With MS |
https://ClinicalTrials.gov/show/NCT03191669 |
Completed |
Hospices Civils de Lyon |
2017-07-07 |
| NCT03164018 |
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis |
https://ClinicalTrials.gov/show/NCT03164018 |
Completed |
Genesis Pharma CNS & Specialty |
2018-12-15 |
| NCT03157830 |
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab |
https://ClinicalTrials.gov/show/NCT03157830 |
Recruiting |
Providence Health & Services |
2021-06-30 |
| NCT03151941 |
Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study |
https://ClinicalTrials.gov/show/NCT03151941 |
Completed |
Solent NHS Trust |
2017-08-31 |
| NCT03135327 |
Clinical Applications of Advanced Ophthalmic Imaging |
https://ClinicalTrials.gov/show/NCT03135327 |
Recruiting |
University of Miami |
2020-12-31 |
| NCT03134573 |
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study |
https://ClinicalTrials.gov/show/NCT03134573 |
Completed |
Bayer |
2018-05-09 |
| NCT03122873 |
Quantitation of McArdle’s Sign and Evaluation of Specificity for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03122873 |
Completed |
Mayo Clinic |
2017-06-30 |
| NCT03111394 |
Study of myMS in Participants With a Diagnosis of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03111394 |
Active, not recruiting |
University of Southern California |
2020-12-31 |
| NCT03108573 |
Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters |
https://ClinicalTrials.gov/show/NCT03108573 |
Completed |
Fondation Ophtalmologique Adolphe de Rothschild |
2013-07-31 |
| NCT03087136 |
A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil |
https://ClinicalTrials.gov/show/NCT03087136 |
Recruiting |
Pontificia Universidade Católica do Rio Grande do Sul |
2019-03-31 |
| NCT03066752 |
Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes |
https://ClinicalTrials.gov/show/NCT03066752 |
Completed |
The Hospital for Sick Children |
2017-11-24 |
| NCT03052595 |
Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance |
https://ClinicalTrials.gov/show/NCT03052595 |
Recruiting |
Slovak Academy of Sciences |
2020-06-30 |
| NCT03047460 |
Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting |
https://ClinicalTrials.gov/show/NCT03047460 |
Completed |
Clinique Neuro-Outaouais |
2018-01-31 |
| NCT03033355 |
Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder |
https://ClinicalTrials.gov/show/NCT03033355 |
Completed |
The Methodist Hospital System |
2019-03-31 |
| NCT03025269 |
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03025269 |
Enrolling by invitation |
University at Buffalo |
2021-04-30 |
| NCT03004794 |
Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort |
https://ClinicalTrials.gov/show/NCT03004794 |
Completed |
Cairo University |
2016-08-31 |
| NCT03004079 |
Clinical Importance of Glucose Regulation in Relapsing MS |
https://ClinicalTrials.gov/show/NCT03004079 |
Recruiting |
University of Virginia |
2020-09-30 |
| NCT02994121 |
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region |
https://ClinicalTrials.gov/show/NCT02994121 |
Recruiting |
University of Pittsburgh |
2047-01-31 |
| NCT02969304 |
Study of Utilization Patterns of Dimethyl Fumarate in Germany |
https://ClinicalTrials.gov/show/NCT02969304 |
Completed |
Biogen |
2017-03-02 |
| NCT02966808 |
Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02966808 |
Recruiting |
Hospital General Universitario Gregorio Marañon |
2020-12-31 |
| NCT02965170 |
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS |
https://ClinicalTrials.gov/show/NCT02965170 |
Completed |
Rocky Mountain MS Research Group, LLC |
2017-12-31 |
| NCT02921035 |
Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02921035 |
Active, not recruiting |
Merck KGaA, Darmstadt, Germany |
2020-06-30 |
| NCT02913209 |
Quantitative Fatigue and Muscle Performance in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02913209 |
Active, not recruiting |
Washington D.C. Veterans Affairs Medical Center |
2018-10-31 |
| NCT02907281 |
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02907281 |
Completed |
Novartis |
2017-07-24 |
| NCT02896933 |
Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02896933 |
Completed |
Fondation Ophtalmologique Adolphe de Rothschild |
2015-01-31 |
| NCT02898974 |
Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02898974 |
Completed |
Colorado State University |
2017-10-31 |
| NCT02893683 |
Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02893683 |
Completed |
Fondation Ophtalmologique Adolphe de Rothschild |
2017-05-15 |
| NCT02887352 |
French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02887352 |
Recruiting |
Fondation Ophtalmologique Adolphe de Rothschild |
2020-01-31 |
| NCT02869360 |
Correlation Between PET and Advanced MRI in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02869360 |
Completed |
University of British Columbia |
2019-10-02 |
| NCT02852317 |
Urinary Markers of Detrusor Overactivity in Spina Bifida Patients |
https://ClinicalTrials.gov/show/NCT02852317 |
Completed |
Rennes University Hospital |
2017-03-29 |
| NCT02845635 |
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02845635 |
Recruiting |
Duke University |
2025-08-31 |
| NCT02814487 |
MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment. |
https://ClinicalTrials.gov/show/NCT02814487 |
Completed |
Ad scientiam |
2016-09-30 |
| NCT02799199 |
Fingolimod Real World Experience: the French Grand-Est Cohort |
https://ClinicalTrials.gov/show/NCT02799199 |
Completed |
CHU de Reims |
2015-10-31 |
| NCT02789670 |
Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02789670 |
Recruiting |
University Hospital, Lille |
2020-07-31 |
| NCT02776072 |
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT02776072 |
Completed |
Biogen |
2016-12-31 |
| NCT02749396 |
EPID Multiple Sclerosis Pregnancy Study |
https://ClinicalTrials.gov/show/NCT02749396 |
Completed |
Bayer |
2018-08-14 |
| NCT02740296 |
Depression and Immune Function in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT02740296 |
Completed |
Charite University, Berlin, Germany |
2017-06-30 |
| NCT02736279 |
Impact of Tecfidera on Gut Microbiota |
https://ClinicalTrials.gov/show/NCT02736279 |
Recruiting |
EvergreenHealth |
2020-06-30 |
| NCT02695394 |
Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study |
https://ClinicalTrials.gov/show/NCT02695394 |
Completed |
Charite University, Berlin, Germany |
2016-12-31 |
| NCT02677077 |
Clinical Disease Activity With Long Term Natalizumab Treatment |
https://ClinicalTrials.gov/show/NCT02677077 |
Completed |
Biogen |
2016-08-18 |
| NCT02679885 |
Teriflunomide Male Transmission Study |
https://ClinicalTrials.gov/show/NCT02679885 |
Completed |
Griffin Hospital |
2018-08-31 |
| NCT02664324 |
MSPT Device Usability Study |
https://ClinicalTrials.gov/show/NCT02664324 |
Completed |
Biogen |
2016-04-30 |
| NCT02652091 |
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction |
https://ClinicalTrials.gov/show/NCT02652091 |
Completed |
Bayer |
2017-08-11 |
| NCT02651545 |
Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02651545 |
Recruiting |
State University of New York at Buffalo |
2020-11-15 |
| NCT02623946 |
Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02623946 |
Active, not recruiting |
Clinique Neuro-Outaouais |
2020-12-31 |
| NCT02612935 |
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02612935 |
Completed |
Lumos Labs, Inc. |
2017-02-28 |
| NCT02601131 |
Post-transfusion Platelet Count |
https://ClinicalTrials.gov/show/NCT02601131 |
Completed |
Region Skane |
2016-09-30 |
| NCT02588053 |
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? |
https://ClinicalTrials.gov/show/NCT02588053 |
Completed |
University of Colorado, Denver |
2018-12-31 |
| NCT02592265 |
Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden |
https://ClinicalTrials.gov/show/NCT02592265 |
Completed |
Lille Catholic University |
2015-08-31 |
| NCT04145284 |
Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS |
https://ClinicalTrials.gov/show/NCT04145284 |
Completed |
Biogen |
2020-04-30 |
| NCT01617395 |
Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility |
https://ClinicalTrials.gov/show/NCT01617395 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00493298 |
Tysabri Observational Program |
https://ClinicalTrials.gov/show/NCT00493298 |
Active, not recruiting |
Biogen |
2029-01-03 |
| NCT02559765 |
Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK. |
https://ClinicalTrials.gov/show/NCT02559765 |
Completed |
University of Glasgow |
2015-11-30 |
| NCT02549703 |
Mitochondrial Dysfunction and Disease Progression |
https://ClinicalTrials.gov/show/NCT02549703 |
Completed |
Icahn School of Medicine at Mount Sinai |
2018-09-27 |
| NCT02519413 |
Tecfidera Lymphocyte Chart Review |
https://ClinicalTrials.gov/show/NCT02519413 |
Completed |
Biogen |
2016-02-29 |
| NCT02504840 |
Natural History of Multiple Sclerosis and Its Mimickers |
https://ClinicalTrials.gov/show/NCT02504840 |
Completed |
National Institutes of Health Clinical Center (CC) |
2020-03-18 |
| NCT02486640 |
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon |
https://ClinicalTrials.gov/show/NCT02486640 |
Completed |
Bayer |
2019-10-31 |
| NCT02486562 |
iConquerMSâ„¢ - A Patient-Powered Research Network for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02486562 |
Recruiting |
Accelerated Cure Project for Multiple Sclerosis |
2026-10-31 |
| NCT02440126 |
Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk |
https://ClinicalTrials.gov/show/NCT02440126 |
Recruiting |
Rocky Mountain MS Research Group, LLC |
2017-03-31 |
| NCT02433028 |
Swiss Multiple Sclerosis Cohort-Study |
https://ClinicalTrials.gov/show/NCT02433028 |
Recruiting |
University Hospital, Basel, Switzerland |
2042-01-31 |
| NCT02418897 |
Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02418897 |
Completed |
Texas Tech University Health Sciences Center |
2016-11-30 |
| NCT02398149 |
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02398149 |
Completed |
Mount Sinai Rehabilitation Hospital |
2016-10-31 |
| NCT02386566 |
Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab |
https://ClinicalTrials.gov/show/NCT02386566 |
Completed |
Biogen |
2018-01-28 |
| NCT02383550 |
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension |
https://ClinicalTrials.gov/show/NCT02383550 |
Completed |
Clinique Neuro-Outaouais |
2017-08-30 |
| NCT02367222 |
A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrixâ„¢ in Manitoba, Canada |
https://ClinicalTrials.gov/show/NCT02367222 |
Completed |
University of Manitoba |
2015-08-31 |
| NCT02369224 |
Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics |
https://ClinicalTrials.gov/show/NCT02369224 |
Completed |
Brown, Theodore R., M.D., MPH |
2016-02-29 |
| NCT02346279 |
Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists |
https://ClinicalTrials.gov/show/NCT02346279 |
Completed |
Institut fuer Physiotherapieforschung |
2013-10-31 |
| NCT02330965 |
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02330965 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2017-07-12 |
| NCT02335892 |
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod |
https://ClinicalTrials.gov/show/NCT02335892 |
Completed |
Novartis |
2017-02-01 |
| NCT02313285 |
A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 |
https://ClinicalTrials.gov/show/NCT02313285 |
Active, not recruiting |
Sanofi |
2022-04-30 |
| NCT02308670 |
Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02308670 |
Completed |
University at Buffalo |
2016-10-31 |
| NCT02308579 |
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases |
https://ClinicalTrials.gov/show/NCT02308579 |
Completed |
University at Buffalo |
2015-03-31 |
| NCT02307877 |
Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate |
https://ClinicalTrials.gov/show/NCT02307877 |
Active, not recruiting |
University of Colorado, Denver |
2020-03-31 |
| NCT02287948 |
Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects |
https://ClinicalTrials.gov/show/NCT02287948 |
Completed |
University Hospital of Ferrara |
2015-12-31 |
| NCT02275741 |
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02275741 |
Completed |
University of Rostock |
2015-09-30 |
| NCT02277964 |
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod |
https://ClinicalTrials.gov/show/NCT02277964 |
Completed |
University Hospital, Basel, Switzerland |
2016-08-31 |
| NCT02247310 |
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon |
https://ClinicalTrials.gov/show/NCT02247310 |
Completed |
Bayer |
2016-07-19 |
| NCT02230969 |
Plegridy Observational Program |
https://ClinicalTrials.gov/show/NCT02230969 |
Active, not recruiting |
Biogen |
2022-01-20 |
| NCT02225977 |
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. |
https://ClinicalTrials.gov/show/NCT02225977 |
Completed |
University of Southern California |
2016-12-31 |
| NCT02207075 |
Measuring Active Microglia in Progressive Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02207075 |
Active, not recruiting |
Weill Medical College of Cornell University |
2020-06-30 |
| NCT02159573 |
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) |
https://ClinicalTrials.gov/show/NCT02159573 |
Completed |
Biogen |
2015-01-31 |
| NCT02157064 |
Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02157064 |
Active, not recruiting |
StemGenex |
2019-05-31 |
| NCT02142946 |
Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study |
https://ClinicalTrials.gov/show/NCT02142946 |
Recruiting |
University Hospital, Basel, Switzerland |
2020-12-31 |
| NCT02139696 |
Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation |
https://ClinicalTrials.gov/show/NCT02139696 |
Completed |
Turku University Hospital |
2015-01-31 |
| NCT02137109 |
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri |
https://ClinicalTrials.gov/show/NCT02137109 |
Completed |
Biogen |
2015-10-31 |
| NCT02137707 |
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya |
https://ClinicalTrials.gov/show/NCT02137707 |
Completed |
McGill University |
2017-11-30 |
| NCT02121444 |
BAY86-5046 (Betaseron), Non Interventional Studies |
https://ClinicalTrials.gov/show/NCT02121444 |
Completed |
Bayer |
2016-03-09 |
| NCT02118298 |
Allocentric Memory in MS and Resting State Functional MRI |
https://ClinicalTrials.gov/show/NCT02118298 |
Completed |
Yale University |
2016-04-30 |
| NCT02099370 |
Adherence to Treatment With Tecfideraâ„¢ in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02099370 |
Completed |
University of South Florida |
2016-01-31 |
| NCT02082002 |
Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino |
https://ClinicalTrials.gov/show/NCT02082002 |
Completed |
Ospedale Civico, Lugano |
2018-12-21 |
| NCT02076841 |
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen |
https://ClinicalTrials.gov/show/NCT02076841 |
Completed |
Biogen |
2016-02-29 |
| NCT01285479 |
Pregnancy Registry Trial |
https://ClinicalTrials.gov/show/NCT01285479 |
Recruiting |
Novartis |
2030-07-31 |
| NCT01281657 |
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program |
https://ClinicalTrials.gov/show/NCT01281657 |
Completed |
Novartis |
2012-07-31 |
| NCT01272128 |
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study |
https://ClinicalTrials.gov/show/NCT01272128 |
Completed |
Biogen |
2014-09-30 |
| NCT01272596 |
Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01272596 |
Completed |
Charite University, Berlin, Germany |
2013-11-30 |
| NCT03360188 |
Pediatric Onset Multiple Sclerosis in Egyptians |
https://ClinicalTrials.gov/show/NCT03360188 |
Completed |
Cairo University |
2015-12-31 |
| NCT02047760 |
Neuroretinal Biomarkers in Neurodegenerative Diseases |
https://ClinicalTrials.gov/show/NCT02047760 |
Completed |
University of Edinburgh |
2016-02-29 |
| NCT04036097 |
Prospective Stratification of Infectious Risks in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04036097 |
Recruiting |
University Hospital, Basel, Switzerland |
2022-04-30 |
| NCT02017808 |
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months |
https://ClinicalTrials.gov/show/NCT02017808 |
Completed |
University at Buffalo |
2014-12-31 |
| NCT03357887 |
Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome |
https://ClinicalTrials.gov/show/NCT03357887 |
Active, not recruiting |
Centre Hospitalier Universitaire de NÄ«mes |
2020-12-31 |
| NCT00794352 |
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System |
https://ClinicalTrials.gov/show/NCT00794352 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT02011204 |
Study of Electrical Impedance Myography (EIM) in ALS |
https://ClinicalTrials.gov/show/NCT02011204 |
Completed |
Skulpt, Inc. |
2016-03-31 |
| NCT02008669 |
Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02008669 |
Completed |
Lille Catholic University |
2017-06-09 |
| NCT01993004 |
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells |
https://ClinicalTrials.gov/show/NCT01993004 |
Completed |
Rutgers, The State University of New Jersey |
2015-12-31 |
| NCT01977287 |
Walking With FES or AFO in People With MS With Foot Drop |
https://ClinicalTrials.gov/show/NCT01977287 |
Completed |
Queen Margaret University |
2016-03-31 |
| NCT01979081 |
Detecting and Addressing Preclinical Disability |
https://ClinicalTrials.gov/show/NCT01979081 |
Completed |
McMaster University |
2017-06-30 |
| NCT01945359 |
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design |
https://ClinicalTrials.gov/show/NCT01945359 |
Completed |
Rocky Mountain MS Research Group, LLC |
2014-09-30 |
| NCT01943526 |
Ireland Natalizumab (TYSABRI) Observational Program |
https://ClinicalTrials.gov/show/NCT01943526 |
Completed |
Biogen |
2017-12-31 |
| NCT01931644 |
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions |
https://ClinicalTrials.gov/show/NCT01931644 |
Recruiting |
Sanguine Biosciences |
2025-08-31 |
| NCT01909492 |
Relaxin in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT01909492 |
Recruiting |
Providence Health & Services |
2019-09-30 |
| NCT01903291 |
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS |
https://ClinicalTrials.gov/show/NCT01903291 |
Completed |
Biogen |
2016-02-29 |
| NCT01881191 |
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months |
https://ClinicalTrials.gov/show/NCT01881191 |
Completed |
University at Buffalo |
2015-10-31 |
| NCT01851434 |
Natural History of Optic Neuritis |
https://ClinicalTrials.gov/show/NCT01851434 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-09-05 |
| NCT01847287 |
A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years |
https://ClinicalTrials.gov/show/NCT01847287 |
Completed |
University at Buffalo |
2013-02-28 |
| NCT01846234 |
Sodium Intake in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01846234 |
Completed |
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia |
2013-07-31 |
| NCT01776060 |
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study |
https://ClinicalTrials.gov/show/NCT01776060 |
Active, not recruiting |
Duke University |
2020-12-31 |
| NCT01774123 |
Optical Coherence Tomography in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01774123 |
Completed |
The Cleveland Clinic |
2013-06-30 |
| NCT01765361 |
Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG) |
https://ClinicalTrials.gov/show/NCT01765361 |
Completed |
University Hospital, Basel, Switzerland |
2015-01-31 |
| NCT01749943 |
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01749943 |
Completed |
Brown, Theodore R., M.D., MPH |
2013-07-31 |
| NCT04185688 |
The Reliability and Validity of the Functional Reach Test in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04185688 |
Completed |
Gazi University |
2020-02-07 |
| NCT01737372 |
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01737372 |
Completed |
Rocky Mountain MS Research Group, LLC |
2016-10-31 |
| NCT01723709 |
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort |
https://ClinicalTrials.gov/show/NCT01723709 |
Completed |
Duke University |
2017-05-31 |
| NCT01711255 |
Evaluation of Coagulation in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01711255 |
Completed |
Bastyr University |
2016-05-31 |
| NCT01704183 |
Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01704183 |
Completed |
Kuopio University Hospital |
2014-03-31 |
| NCT01703429 |
Complementary and Alternative Care in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01703429 |
Recruiting |
Bastyr University |
2030-06-30 |
| NCT01695434 |
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months |
https://ClinicalTrials.gov/show/NCT01695434 |
Completed |
University at Buffalo |
2013-02-28 |
| NCT02659956 |
Pathological Basis of MRI Signal Changes in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02659956 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2041-02-26 |
| NCT01652352 |
Experimental Evaluation of Wheelchair-Mounted Robotic Arms |
https://ClinicalTrials.gov/show/NCT01652352 |
Completed |
University of South Florida |
2011-07-31 |
| NCT01626248 |
Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control |
https://ClinicalTrials.gov/show/NCT01626248 |
Completed |
Rocky Mountain MS Research Group, LLC |
2013-03-31 |
| NCT01628315 |
Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study |
https://ClinicalTrials.gov/show/NCT01628315 |
Completed |
University at Buffalo |
2009-03-31 |
| NCT01601119 |
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients |
https://ClinicalTrials.gov/show/NCT01601119 |
Completed |
Merck KGaA, Darmstadt, Germany |
2014-07-31 |
| NCT01601080 |
An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device |
https://ClinicalTrials.gov/show/NCT01601080 |
Completed |
Merck KGaA, Darmstadt, Germany |
2012-10-31 |
| NCT01596881 |
Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01596881 |
Completed |
Oregon Health and Science University |
2017-02-08 |
| NCT01587690 |
Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells |
https://ClinicalTrials.gov/show/NCT01587690 |
Completed |
Rutgers, The State University of New Jersey |
2013-01-31 |
| NCT01592552 |
A Biospecimen and Clinical Data Study on Patients With Alzheimer’s, Multiple Sclerosis, Parkinson’s, and Huntington’s, for Drug & Biomarker Discovery |
https://ClinicalTrials.gov/show/NCT01592552 |
Completed |
Sanguine Biosciences |
2015-03-31 |
| NCT01592474 |
Evaluation of Brain Atrophy in CIS Patients on Avonex |
https://ClinicalTrials.gov/show/NCT01592474 |
Completed |
University at Buffalo |
2011-08-31 |
| NCT01592097 |
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS |
https://ClinicalTrials.gov/show/NCT01592097 |
Completed |
University of Southern California |
2018-04-30 |
| NCT01547351 |
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire |
https://ClinicalTrials.gov/show/NCT01547351 |
Completed |
Mallinckrodt |
2012-09-30 |
| NCT01547234 |
Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01547234 |
Completed |
Carmel Medical Center |
2014-12-31 |
| NCT01535664 |
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT01535664 |
Completed |
Acorda Therapeutics |
2012-05-31 |
| NCT01492023 |
The Effects of Attention Retraining in MS |
https://ClinicalTrials.gov/show/NCT01492023 |
Completed |
Finnish MS Society |
2012-04-30 |
| NCT01491100 |
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01491100 |
Completed |
Bayer |
2016-12-22 |
| NCT01489748 |
Canadian Avonex PEN Productivity Study |
https://ClinicalTrials.gov/show/NCT01489748 |
Completed |
Biogen |
2014-10-31 |
| NCT01480063 |
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice |
https://ClinicalTrials.gov/show/NCT01480063 |
Completed |
Biogen |
2019-02-08 |
| NCT01485003 |
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants |
https://ClinicalTrials.gov/show/NCT01485003 |
Completed |
Biogen |
2018-11-26 |
| NCT01456416 |
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities |
https://ClinicalTrials.gov/show/NCT01456416 |
Completed |
University of Southern California |
2013-04-30 |
| NCT01442194 |
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies |
https://ClinicalTrials.gov/show/NCT01442194 |
Recruiting |
Novartis |
NA |
| NCT01436838 |
China Betaferon Adherence, Coping and Nurse Support Study |
https://ClinicalTrials.gov/show/NCT01436838 |
Completed |
Bayer |
2015-09-30 |
| NCT01414816 |
Betaferon® Regulatory Post-Marketing Surveillance |
https://ClinicalTrials.gov/show/NCT01414816 |
Completed |
Bayer |
2012-07-31 |
| NCT01405872 |
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. |
https://ClinicalTrials.gov/show/NCT01405872 |
Completed |
Biogen |
2013-09-30 |
| NCT01396343 |
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01396343 |
Completed |
University of California, San Francisco |
2018-04-30 |
| NCT01399957 |
Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01399957 |
Completed |
Mount Sinai Rehabilitation Hospital |
2014-09-30 |
| NCT01384825 |
Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases |
https://ClinicalTrials.gov/show/NCT01384825 |
Completed |
Fondazione Italiana Sclerosi Multipla |
2012-09-30 |
| NCT01366040 |
Avonex PEN Satisfaction and Patients Experience Clinical Trial |
https://ClinicalTrials.gov/show/NCT01366040 |
Completed |
Biogen |
2012-05-31 |
| NCT01366027 |
PRISM Registry: Pseudobulbar Affect Registry Series |
https://ClinicalTrials.gov/show/NCT01366027 |
Completed |
Avanir Pharmaceuticals |
2012-09-30 |
| NCT03787446 |
PET Study in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03787446 |
Recruiting |
University of British Columbia |
2020-03-31 |
| NCT01356134 |
Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) |
https://ClinicalTrials.gov/show/NCT01356134 |
Completed |
Genetic Disease Investigators |
2015-04-30 |
| NCT01353547 |
Genes and Environment in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01353547 |
Recruiting |
Columbia University |
2040-10-31 |
| NCT01354665 |
Depression and Fatigue in MS Patients Treated With Betaferon. |
https://ClinicalTrials.gov/show/NCT01354665 |
Completed |
Bayer |
2013-06-30 |
| NCT01335633 |
Psychometric Validation of Cognitive Endpoints |
https://ClinicalTrials.gov/show/NCT01335633 |
Completed |
Kessler Foundation |
2011-08-31 |
| NCT01330498 |
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical |
https://ClinicalTrials.gov/show/NCT01330498 |
Completed |
Rocky Mountain MS Research Group, LLC |
2011-08-31 |
| NCT04450030 |
Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04450030 |
Recruiting |
University Hospital Muenster |
2020-08-31 |
| NCT04438954 |
Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels |
https://ClinicalTrials.gov/show/NCT04438954 |
Completed |
Ankara Yildirim Beyazıt University |
2020-06-05 |
| NCT04408742 |
Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04408742 |
Completed |
Ankara Yildirim Beyazıt University |
2019-10-20 |
| NCT04390126 |
COVID-19 Related Lockdown Effects On Chronic Diseases |
https://ClinicalTrials.gov/show/NCT04390126 |
Active, not recruiting |
Centre Hospitalier Universitaire Dijon |
2021-05-07 |
| NCT04403594 |
Functional Intermuscular Reduction of Spasticity |
https://ClinicalTrials.gov/show/NCT04403594 |
Recruiting |
University of Oklahoma |
2020-12-18 |
| NCT04386863 |
Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study |
https://ClinicalTrials.gov/show/NCT04386863 |
Recruiting |
Fondazione Don Carlo Gnocchi Onlus |
2020-07-07 |
| NCT04355611 |
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO |
https://ClinicalTrials.gov/show/NCT04355611 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2022-04-20 |
| NCT04306939 |
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study |
https://ClinicalTrials.gov/show/NCT04306939 |
Recruiting |
University of Pittsburgh |
2025-12-01 |
| NCT04300868 |
Immunisation Status and Safety of Vaccines in Italian MS Patients |
https://ClinicalTrials.gov/show/NCT04300868 |
Enrolling by invitation |
University of Siena |
2020-12-31 |
| NCT04288011 |
Validation of the BeCare Multiple Sclerosis Assessment App |
https://ClinicalTrials.gov/show/NCT04288011 |
Enrolling by invitation |
BeCare Link LLC |
2021-08-26 |
| NCT04286828 |
Position Sense, Balance, and Dual Task Performance at the Menstrual Cycle in Females With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04286828 |
Completed |
Ankara Yildirim Beyazıt University |
2019-10-20 |
| NCT04283071 |
Kinematic Assessment In Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04283071 |
Recruiting |
The Leeds Teaching Hospitals NHS Trust |
2021-05-01 |
| NCT04281160 |
Patient Centered Outcomes Analysis for MS Using a Mobile Application |
https://ClinicalTrials.gov/show/NCT04281160 |
Enrolling by invitation |
BeCare Link LLC |
2020-09-01 |
| NCT04265092 |
Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04265092 |
Completed |
Pôle Saint Hélier |
2014-03-31 |
| NCT04252599 |
Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients. |
https://ClinicalTrials.gov/show/NCT04252599 |
Recruiting |
Universidad de Granada |
2019-12-02 |
| NCT04240379 |
Metacognition Assessment in Patient With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04240379 |
Recruiting |
University Hospital, Grenoble |
2021-08-31 |
| NCT04239820 |
Effect of Cladribine Treatment on Microglial Activation in the CNS |
https://ClinicalTrials.gov/show/NCT04239820 |
Recruiting |
Turku University Hospital |
2023-08-31 |
| NCT04231253 |
MUltiple Sclerosis : T Cell / B Cell Exploration |
https://ClinicalTrials.gov/show/NCT04231253 |
Recruiting |
Rennes University Hospital |
2023-02-28 |
| NCT04228328 |
Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04228328 |
Recruiting |
Haute Ecole de Santé Vaud |
2021-01-30 |
| NCT04221191 |
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP |
https://ClinicalTrials.gov/show/NCT04221191 |
Recruiting |
Biogen |
2021-08-19 |
| NCT04210960 |
Correlation of Serum Lactate and Activity of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04210960 |
Recruiting |
Mansoura University Hospital |
2020-05-01 |
| NCT04202055 |
Immunologic Biomarker Profile of Cerebrospinal Fluid |
https://ClinicalTrials.gov/show/NCT04202055 |
Completed |
Centre Hospitalier Universitaire de NÄ«mes |
2019-08-31 |
| NCT04183751 |
The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in MS Patients |
https://ClinicalTrials.gov/show/NCT04183751 |
Recruiting |
Marmara University |
2020-04-21 |
| NCT04185792 |
Polish Translation and Validation of NBSS, Qualiveen and SF-Qualiveen |
https://ClinicalTrials.gov/show/NCT04185792 |
Recruiting |
Jagiellonian University |
2020-09-18 |
| NCT04153773 |
OCT and Early Cognitive Impairment in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04153773 |
Completed |
Mansoura University Hospital |
2019-06-01 |
| NCT04148313 |
A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04148313 |
Recruiting |
ProgenaBiome |
2023-03-31 |
| NCT04133779 |
Observational Study on Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04133779 |
Completed |
Fondazione Italiana Sclerosi Multipla |
2012-05-30 |
| NCT04132037 |
An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT04132037 |
Active, not recruiting |
University Hospital, Toulouse |
2021-12-31 |
| NCT04131764 |
Diagnosis of ON With or Without MS or NMOSD |
https://ClinicalTrials.gov/show/NCT04131764 |
Enrolling by invitation |
University of Kentucky |
2021-12-31 |
| NCT04131673 |
MS and NMOSD in African-Americans |
https://ClinicalTrials.gov/show/NCT04131673 |
Enrolling by invitation |
University of Kentucky |
2023-12-31 |
| NCT04126772 |
Multimodal Imaging of MS Reveals the Smoldering Inflammation |
https://ClinicalTrials.gov/show/NCT04126772 |
Recruiting |
Turku University Hospital |
2022-01-31 |
| NCT04123353 |
Scan-Rescan Sub-Study of MS PATHS |
https://ClinicalTrials.gov/show/NCT04123353 |
Completed |
Biogen |
2017-05-09 |
| NCT04114994 |
Longitudinal Cognitive Assessment by BoCA |
https://ClinicalTrials.gov/show/NCT04114994 |
Recruiting |
Alzheimer’s Light LLC |
2029-10-01 |
| NCT04115930 |
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients |
https://ClinicalTrials.gov/show/NCT04115930 |
Completed |
University of Eastern Finland |
2019-06-13 |
| NCT04095377 |
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019. |
https://ClinicalTrials.gov/show/NCT04095377 |
Active, not recruiting |
QuantalX Neuroscience |
2020-03-31 |
| NCT04082468 |
VALIDATE: Factor VIII Trending for MS Relapse |
https://ClinicalTrials.gov/show/NCT04082468 |
Recruiting |
St. Joseph’s Hospital and Medical Center, Phoenix |
2021-12-01 |
| NCT04080687 |
Effect of Ankle-foot Orthoses on Balance Confidence |
https://ClinicalTrials.gov/show/NCT04080687 |
Recruiting |
University Rehabilitation Institute, Republic of Slovenia |
2020-05-31 |
| NCT04075968 |
The Effect of Cognitive Group Exercise Combined With Physical Exercise in MS |
https://ClinicalTrials.gov/show/NCT04075968 |
Completed |
Istanbul Physical Medicine Rehabilitation Training and Research Hospital |
2019-11-15 |
| NCT04082260 |
Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response |
https://ClinicalTrials.gov/show/NCT04082260 |
Recruiting |
University Hospital Muenster |
2022-01-31 |
| NCT04063852 |
PTNS on Urinary and Global Quality of Life in MS Patients |
https://ClinicalTrials.gov/show/NCT04063852 |
Recruiting |
University of Michigan |
2021-12-31 |
| NCT04057222 |
Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04057222 |
Completed |
Pierre and Marie Curie University |
2019-09-06 |
| NCT04053374 |
Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04053374 |
Recruiting |
University College, London |
2020-06-30 |
| NCT04024969 |
DiagnosE Using the Central veIn SIgn |
https://ClinicalTrials.gov/show/NCT04024969 |
Recruiting |
Nottingham University Hospitals NHS Trust |
2022-05-31 |
| NCT04024085 |
Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04024085 |
Recruiting |
Pierre and Marie Curie University |
2019-07-31 |
| NCT04022564 |
Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04022564 |
Active, not recruiting |
China Medical University Hospital |
2020-05-20 |
| NCT03347370 |
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03347370 |
Completed |
Biogen |
2019-07-31 |
| NCT03993275 |
Exergames Balance Program in Neurorehabilitation |
https://ClinicalTrials.gov/show/NCT03993275 |
Completed |
Klinik Valens |
2020-01-15 |
| NCT03981003 |
Serum Neurofilament-light Chain Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03981003 |
Recruiting |
Centre Hospitalier Universitaire de NÄ«mes |
2023-06-30 |
| NCT03963310 |
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03963310 |
Recruiting |
Fondation Ophtalmologique Adolphe de Rothschild |
2024-05-31 |
| NCT03945006 |
Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence |
https://ClinicalTrials.gov/show/NCT03945006 |
Completed |
Ankara Yildirim Beyazıt University |
2019-04-20 |
| NCT03942952 |
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. |
https://ClinicalTrials.gov/show/NCT03942952 |
Recruiting |
University of Texas Southwestern Medical Center |
2022-05-31 |
| NCT03933215 |
A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) |
https://ClinicalTrials.gov/show/NCT03933215 |
Recruiting |
EMD Serono |
2023-11-29 |
| NCT03933202 |
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) |
https://ClinicalTrials.gov/show/NCT03933202 |
Recruiting |
EMD Serono |
2023-05-03 |
| NCT03927092 |
Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire |
https://ClinicalTrials.gov/show/NCT03927092 |
Completed |
Ege University |
2016-05-31 |
| NCT03917589 |
Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS) |
https://ClinicalTrials.gov/show/NCT03917589 |
Recruiting |
Rennes University Hospital |
2021-06-20 |
| NCT03893344 |
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry |
https://ClinicalTrials.gov/show/NCT03893344 |
Completed |
Assiut University |
2020-05-20 |
| NCT03873389 |
Ocrelizumab Effects on the Metabolome in MS |
https://ClinicalTrials.gov/show/NCT03873389 |
Recruiting |
Johns Hopkins University |
2023-01-31 |
| NCT03886753 |
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products |
https://ClinicalTrials.gov/show/NCT03886753 |
Active, not recruiting |
Children’s Hospital of Philadelphia |
2020-12-31 |
| NCT03863379 |
Sarcopenic Obesity in Neurodisabilities |
https://ClinicalTrials.gov/show/NCT03863379 |
Enrolling by invitation |
Dionyssiotis, Yannis, M.D. |
2021-05-31 |
| NCT03067025 |
Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03067025 |
Completed |
The Hospital for Sick Children |
2019-09-16 |
| NCT03854123 |
Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics |
https://ClinicalTrials.gov/show/NCT03854123 |
Recruiting |
University Hospital, Bordeaux |
2020-12-31 |
| NCT03841903 |
Spinal Cord Analysis in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03841903 |
Completed |
University Hospital, Basel, Switzerland |
2020-03-24 |
| NCT03806387 |
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment |
https://ClinicalTrials.gov/show/NCT03806387 |
Recruiting |
University of Aarhus |
2019-04-30 |
| NCT03808142 |
PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon |
https://ClinicalTrials.gov/show/NCT03808142 |
Completed |
Bayer |
2020-04-20 |
| NCT03796247 |
Alexithymia Frequency and Interhemispheric Transfer in Patients With a First Demyelinating Event |
https://ClinicalTrials.gov/show/NCT03796247 |
Completed |
University Hospital, Lille |
2016-05-31 |
| NCT03784547 |
Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM |
https://ClinicalTrials.gov/show/NCT03784547 |
Recruiting |
Hospital Italiano de Buenos Aires |
2019-08-01 |
| NCT03757065 |
Cell Surface Marker Expression in Autoimmune Diseases |
https://ClinicalTrials.gov/show/NCT03757065 |
Enrolling by invitation |
Alpine Immune Sciences, Inc. |
2020-03-31 |
| NCT03756142 |
Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT03756142 |
Recruiting |
Lille Catholic University |
2020-11-05 |
| NCT03736902 |
Views on Physical Activity Following a Relapse in People With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03736902 |
Completed |
City, University of London |
2019-05-14 |
| NCT03723356 |
Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT03723356 |
Recruiting |
NYU Langone Health |
2021-12-13 |
| NCT03718026 |
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03718026 |
Completed |
Gazi University |
2018-11-16 |
| NCT03718247 |
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS |
https://ClinicalTrials.gov/show/NCT03718247 |
Recruiting |
University of Virginia |
2022-10-31 |
| NCT03703180 |
Vision Assessment With the Quick Contrast Sensitivity Function (qCSF) Method in Healthy Controls and MS |
https://ClinicalTrials.gov/show/NCT03703180 |
Recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2021-02-28 |
| NCT03656055 |
Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03656055 |
Recruiting |
University Hospital, Lille |
2019-12-31 |
| NCT03655093 |
Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03655093 |
Completed |
Rennes University Hospital |
2017-07-03 |
| NCT03653585 |
Cortical Lesions in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03653585 |
Recruiting |
Danish Research Centre for Magnetic Resonance |
2020-07-31 |
| NCT03647722 |
Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab). |
https://ClinicalTrials.gov/show/NCT03647722 |
Recruiting |
University of Southern California |
2022-09-30 |
| NCT03632473 |
Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03632473 |
Recruiting |
University Hospital, Basel, Switzerland |
2022-07-31 |
| NCT03597451 |
The Effects of Muscles Strength on Physical Performance in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03597451 |
Completed |
Gazi University |
2020-02-28 |
| NCT03594357 |
Cognitive Functions in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03594357 |
Completed |
Gazi University |
2018-12-21 |
| NCT03586986 |
Risk Factors in Early Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03586986 |
Recruiting |
University of Colorado, Denver |
2020-05-30 |
| NCT03593590 |
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03593590 |
Recruiting |
Hoffmann-La Roche |
2025-07-26 |
| NCT03577977 |
Betaferon Use in Children and Adolescents With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03577977 |
Completed |
Bayer |
2009-04-15 |
| NCT03561402 |
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) |
https://ClinicalTrials.gov/show/NCT03561402 |
Recruiting |
McGill University |
2018-08-30 |
| NCT03562975 |
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus |
https://ClinicalTrials.gov/show/NCT03562975 |
Recruiting |
University of South Florida |
2020-08-31 |
| NCT03541226 |
Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS) |
https://ClinicalTrials.gov/show/NCT03541226 |
Recruiting |
University Hospital, Lille |
2021-09-30 |
| NCT03508284 |
Dual-Task Performance in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03508284 |
Completed |
Gazi University |
2019-05-16 |
| NCT03464448 |
Mechanistic Studies of Teriflunomide in RRMS |
https://ClinicalTrials.gov/show/NCT03464448 |
Recruiting |
University of Michigan |
2021-10-31 |
| NCT03451175 |
Reproductibility of Cystometry in Multiple Sclerosis Patient |
https://ClinicalTrials.gov/show/NCT03451175 |
Completed |
Pierre and Marie Curie University |
2017-11-01 |
| NCT03438357 |
Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI |
https://ClinicalTrials.gov/show/NCT03438357 |
Active, not recruiting |
Centre Hospitalier Universitaire de NÄ«mes |
2020-11-30 |
| NCT01271699 |
Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01271699 |
Completed |
Centogene AG Rostock |
2019-12-01 |
| NCT01233245 |
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program |
https://ClinicalTrials.gov/show/NCT01233245 |
Completed |
Bayer |
2009-06-30 |
| NCT01235455 |
Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors |
https://ClinicalTrials.gov/show/NCT01235455 |
Completed |
Bayer |
NA |
| NCT01206023 |
Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples |
https://ClinicalTrials.gov/show/NCT01206023 |
Completed |
Carmel Medical Center |
2011-11-30 |
| NCT01207648 |
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) |
https://ClinicalTrials.gov/show/NCT01207648 |
Completed |
EMD Serono |
2011-07-31 |
| NCT01195870 |
Assessment of Patient Use of a New Device: RebiSmart |
https://ClinicalTrials.gov/show/NCT01195870 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-09-30 |
| NCT01195857 |
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration |
https://ClinicalTrials.gov/show/NCT01195857 |
Completed |
Merck KGaA, Darmstadt, Germany |
2009-09-30 |
| NCT01185717 |
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT01185717 |
Completed |
Biogen |
2012-05-31 |
| NCT01184833 |
Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01184833 |
Completed |
Bayer |
NA |
| NCT01158183 |
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01158183 |
Completed |
Bayer |
2009-09-30 |
| NCT01157728 |
Early Cognitive Impairment in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01157728 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2010-12-31 |
| NCT01142583 |
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01142583 |
Completed |
Merck KGaA, Darmstadt, Germany |
2009-08-31 |
| NCT01142557 |
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01142557 |
Completed |
Merck KGaA, Darmstadt, Germany |
2005-11-30 |
| NCT01142518 |
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone |
https://ClinicalTrials.gov/show/NCT01142518 |
Completed |
Merck KGaA, Darmstadt, Germany |
2009-03-31 |
| NCT01142492 |
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) |
https://ClinicalTrials.gov/show/NCT01142492 |
Completed |
Merck KGaA, Darmstadt, Germany |
2008-07-31 |
| NCT01141751 |
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy |
https://ClinicalTrials.gov/show/NCT01141751 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-06-30 |
| NCT01142453 |
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients |
https://ClinicalTrials.gov/show/NCT01142453 |
Completed |
Merck KGaA, Darmstadt, Germany |
2008-06-30 |
| NCT01128075 |
Treatment Adherence When Using RebiSmartâ„¢ in Relapsing Multiple Sclerosis Subjects |
https://ClinicalTrials.gov/show/NCT01128075 |
Completed |
Merck KGaA, Darmstadt, Germany |
2014-04-30 |
| NCT01125475 |
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects |
https://ClinicalTrials.gov/show/NCT01125475 |
Completed |
Merck KGaA, Darmstadt, Germany |
2012-03-31 |
| NCT01118130 |
Pharmacogenomics of Drug Safety in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01118130 |
Recruiting |
University of British Columbia |
2020-12-31 |
| NCT01112657 |
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period |
https://ClinicalTrials.gov/show/NCT01112657 |
Completed |
Merck KGaA, Darmstadt, Germany |
2014-10-31 |
| NCT01117090 |
Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery |
https://ClinicalTrials.gov/show/NCT01117090 |
Completed |
MedtronicNeuro |
2012-09-30 |
| NCT01112345 |
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters |
https://ClinicalTrials.gov/show/NCT01112345 |
Completed |
Merck KGaA, Darmstadt, Germany |
2012-09-30 |
| NCT01110993 |
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) |
https://ClinicalTrials.gov/show/NCT01110993 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-09-30 |
| NCT01108887 |
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. |
https://ClinicalTrials.gov/show/NCT01108887 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-01-31 |
| NCT01101776 |
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. |
https://ClinicalTrials.gov/show/NCT01101776 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-04-30 |
| NCT01084798 |
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years |
https://ClinicalTrials.gov/show/NCT01084798 |
Completed |
Merck KGaA, Darmstadt, Germany |
2008-12-31 |
| NCT01080573 |
Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01080573 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-04-30 |
| NCT01080053 |
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT01080053 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-05-31 |
| NCT01080040 |
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01080040 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-03-31 |
| NCT01076595 |
Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period |
https://ClinicalTrials.gov/show/NCT01076595 |
Completed |
Bayer |
2013-11-30 |
| NCT01080027 |
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) |
https://ClinicalTrials.gov/show/NCT01080027 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-06-30 |
| NCT01075880 |
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® |
https://ClinicalTrials.gov/show/NCT01075880 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-06-30 |
| NCT01080014 |
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina |
https://ClinicalTrials.gov/show/NCT01080014 |
Completed |
Merck KGaA, Darmstadt, Germany |
2013-04-30 |
| NCT01080001 |
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina |
https://ClinicalTrials.gov/show/NCT01080001 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-12-31 |
| NCT01075737 |
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers |
https://ClinicalTrials.gov/show/NCT01075737 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-03-31 |
| NCT01079975 |
To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01079975 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-10-31 |
| NCT01074346 |
Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01074346 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-11-30 |
| NCT01070836 |
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab |
https://ClinicalTrials.gov/show/NCT01070836 |
Completed |
Biogen |
2015-11-30 |
| NCT01070823 |
JC-Virus (JCV) Antibody Program |
https://ClinicalTrials.gov/show/NCT01070823 |
Completed |
Biogen |
2012-06-30 |
| NCT01067573 |
The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment |
https://ClinicalTrials.gov/show/NCT01067573 |
Completed |
University of South Florida |
NA |
| NCT01070719 |
Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort |
https://ClinicalTrials.gov/show/NCT01070719 |
Completed |
Rocky Mountain MS Research Group, LLC |
2010-05-31 |
| NCT01065090 |
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01065090 |
Completed |
Biogen |
2014-01-31 |
| NCT01044576 |
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01044576 |
Completed |
Imperial College London |
2012-11-30 |
| NCT01034644 |
Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15) |
https://ClinicalTrials.gov/show/NCT01034644 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-11-30 |
| NCT01020370 |
Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies |
https://ClinicalTrials.gov/show/NCT01020370 |
Completed |
Wayne State University |
NA |
| NCT01013350 |
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials |
https://ClinicalTrials.gov/show/NCT01013350 |
Completed |
EMD Serono |
2018-10-25 |
| NCT00963833 |
Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00963833 |
Completed |
Bayer |
2016-04-12 |
| NCT00937677 |
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study |
https://ClinicalTrials.gov/show/NCT00937677 |
Completed |
University at Buffalo |
2009-12-31 |
| NCT00928967 |
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT00928967 |
Completed |
Bayer |
2010-03-31 |
| NCT00919217 |
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms |
https://ClinicalTrials.gov/show/NCT00919217 |
Recruiting |
University of Louisville |
2020-12-31 |
| NCT00902135 |
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) |
https://ClinicalTrials.gov/show/NCT00902135 |
Completed |
Bayer |
2013-12-31 |
| NCT00888277 |
Bayer/Cognitive Assessments With Multiple Sclerosis Subjects |
https://ClinicalTrials.gov/show/NCT00888277 |
Completed |
University of Louisville |
2009-12-31 |
| NCT00884481 |
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS |
https://ClinicalTrials.gov/show/NCT00884481 |
Completed |
Biogen |
2011-06-30 |
| NCT00883142 |
Functional and Physiological Responses to Lokomat Therapy (Pilot Study) |
https://ClinicalTrials.gov/show/NCT00883142 |
Completed |
VA Office of Research and Development |
2012-08-31 |
| NCT00882453 |
Physical Activity and Fatigue in Early Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00882453 |
Completed |
Bayer |
2011-03-31 |
| NCT00873340 |
Physical Disability in Patients Treated With Betaferon |
https://ClinicalTrials.gov/show/NCT00873340 |
Completed |
Bayer |
2011-01-31 |
| NCT00859482 |
Differential Immune Effects of Natalizumab |
https://ClinicalTrials.gov/show/NCT00859482 |
Completed |
Cantonal Hospital of St. Gallen |
2007-07-31 |
| NCT04338646 |
Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04338646 |
Recruiting |
Pierre and Marie Curie University |
2020-04-15 |
| NCT04157283 |
Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities |
https://ClinicalTrials.gov/show/NCT04157283 |
Recruiting |
Mansoura University Hospital |
2020-05-05 |
| NCT03926637 |
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03926637 |
Recruiting |
Biogen |
2022-09-01 |
| NCT02880553 |
Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02880553 |
Completed |
Fondation Ophtalmologique Adolphe de Rothschild |
2017-03-09 |
| NCT01031459 |
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial. |
https://ClinicalTrials.gov/show/NCT01031459 |
Completed |
Bayer |
2010-12-31 |
| NCT02021162 |
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02021162 |
Completed |
University at Buffalo |
2018-09-30 |
| NCT03686826 |
Feasibility and Reliability of Multimodal Evoked Potentials |
https://ClinicalTrials.gov/show/NCT03686826 |
Completed |
University Hospital, Basel, Switzerland |
2017-09-15 |
| NCT02823951 |
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® |
https://ClinicalTrials.gov/show/NCT02823951 |
Completed |
IMS HEALTH GmbH & Co. OHG |
2017-04-30 |
| NCT00812474 |
Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00812474 |
Completed |
Sunnybrook Health Sciences Centre |
2009-06-30 |
| NCT01706055 |
Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) |
https://ClinicalTrials.gov/show/NCT01706055 |
Completed |
Bayer |
2015-09-30 |
| NCT01766063 |
Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon |
https://ClinicalTrials.gov/show/NCT01766063 |
Completed |
Bayer |
2017-01-09 |
| NCT03954717 |
Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program |
https://ClinicalTrials.gov/show/NCT03954717 |
Enrolling by invitation |
Shepherd Center, Atlanta GA |
2021-07-28 |
| NCT03332654 |
Stress Urinary Incontinence in Women With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03332654 |
Completed |
Lille Catholic University |
2016-01-31 |
| NCT03134716 |
Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03134716 |
Active, not recruiting |
Turku University Hospital |
2022-04-30 |
| NCT03187847 |
Rehabilitation in Multiple Sclerosis - Sometimes Too Much? |
https://ClinicalTrials.gov/show/NCT03187847 |
Completed |
Klinik Valens |
2018-03-30 |
| NCT02686684 |
Tecfidera Diffusion Tensor Imaging |
https://ClinicalTrials.gov/show/NCT02686684 |
Completed |
University at Buffalo |
2016-10-31 |
| NCT02836327 |
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders |
https://ClinicalTrials.gov/show/NCT02836327 |
Recruiting |
Chinese PLA General Hospital |
2019-09-30 |
| NCT02598167 |
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition |
https://ClinicalTrials.gov/show/NCT02598167 |
Completed |
Hoffmann-La Roche |
2016-02-23 |
| NCT01804660 |
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population |
https://ClinicalTrials.gov/show/NCT01804660 |
Completed |
GeNeuro Innovation SAS |
2013-11-30 |
| NCT01804647 |
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease |
https://ClinicalTrials.gov/show/NCT01804647 |
Completed |
GeNeuro Innovation SAS |
2015-02-28 |
| NCT04371575 |
Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients |
https://ClinicalTrials.gov/show/NCT04371575 |
Completed |
Danish Headache Center |
2019-12-31 |
| NCT01658384 |
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01658384 |
Completed |
Clinique Neuro-Outaouais |
2015-02-28 |
| NCT03941184 |
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity |
https://ClinicalTrials.gov/show/NCT03941184 |
Recruiting |
Mayo Clinic |
2020-12-31 |
| NCT03486665 |
Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients. |
https://ClinicalTrials.gov/show/NCT03486665 |
Recruiting |
Bioimmunate |
2018-09-30 |
| NCT00787657 |
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment |
https://ClinicalTrials.gov/show/NCT00787657 |
Completed |
Bayer |
2013-09-30 |
| NCT00715598 |
Cognitive Testing for the Pain Quality Assessment Scale (PQAS) |
https://ClinicalTrials.gov/show/NCT00715598 |
Completed |
University of Washington |
2010-06-30 |
| NCT00704834 |
Gene Expression Profiles in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00704834 |
Completed |
University of California, Davis |
2017-07-05 |
| NCT00710645 |
Lido Workset Study |
https://ClinicalTrials.gov/show/NCT00710645 |
Completed |
University of California, Davis |
2012-06-30 |
| NCT00704626 |
Serum Auto-Antibodies in Neurological Diseases |
https://ClinicalTrials.gov/show/NCT00704626 |
Enrolling by invitation |
University of California, Davis |
2020-12-31 |
| NCT00702065 |
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment |
https://ClinicalTrials.gov/show/NCT00702065 |
Completed |
EMD Serono |
2010-10-31 |
| NCT00675883 |
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS |
https://ClinicalTrials.gov/show/NCT00675883 |
Completed |
Biogen |
2011-12-31 |
| NCT00618267 |
ATP Expression in Lymphocytes of MS Patients by Means of “ImmuKnow®” Assay. |
https://ClinicalTrials.gov/show/NCT00618267 |
Completed |
Biogen |
2008-12-31 |
| NCT00617383 |
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS |
https://ClinicalTrials.gov/show/NCT00617383 |
Completed |
The University of Texas Health Science Center, Houston |
2010-12-31 |
| NCT00599274 |
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00599274 |
Completed |
Biogen |
NA |
| NCT00544037 |
BENEFIT Extension Study |
https://ClinicalTrials.gov/show/NCT00544037 |
Completed |
Bayer |
2011-01-31 |
| NCT00525343 |
Avonex 15 Year Long Term Follow-up Study |
https://ClinicalTrials.gov/show/NCT00525343 |
Completed |
Biogen |
NA |
| NCT00492570 |
GER-009-06-AVX Early Therapy in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00492570 |
Completed |
Biogen |
2007-10-31 |
| NCT00490906 |
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00490906 |
Completed |
University of Kansas Medical Center |
2009-02-28 |
| NCT00483847 |
TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World |
https://ClinicalTrials.gov/show/NCT00483847 |
Completed |
Biogen |
2014-11-30 |
| NCT00477113 |
TYSABRI Global Observational Program in Safety |
https://ClinicalTrials.gov/show/NCT00477113 |
Completed |
Biogen |
2015-05-31 |
| NCT00468182 |
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00468182 |
Completed |
Rutgers, The State University of New Jersey |
2011-12-31 |
| NCT00461396 |
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron |
https://ClinicalTrials.gov/show/NCT00461396 |
Completed |
Bayer |
2009-06-30 |
| NCT00464074 |
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue |
https://ClinicalTrials.gov/show/NCT00464074 |
Completed |
Biogen |
2010-07-31 |
| NCT00463710 |
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS |
https://ClinicalTrials.gov/show/NCT00463710 |
Completed |
State University of New York at Buffalo |
NA |
| NCT00445367 |
Biobank For MS And Other Demyelinating Diseases |
https://ClinicalTrials.gov/show/NCT00445367 |
Active, not recruiting |
Accelerated Cure Project for Multiple Sclerosis |
2026-10-31 |
| NCT00439257 |
Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron) |
https://ClinicalTrials.gov/show/NCT00439257 |
Completed |
VA Office of Research and Development |
NA |
| NCT00430599 |
The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00430599 |
Completed |
Newcastle-upon-Tyne Hospitals NHS Trust |
NA |
| NCT00424359 |
Ambulation Study in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00424359 |
Completed |
Brown, Theodore R., M.D., MPH |
NA |
| NCT00393588 |
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00393588 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00391352 |
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls |
https://ClinicalTrials.gov/show/NCT00391352 |
Completed |
Waukesha Memorial Hospital |
2012-08-31 |
| NCT00338741 |
Rebif® Pregnancy Registry |
https://ClinicalTrials.gov/show/NCT00338741 |
Completed |
EMD Serono |
2007-10-31 |
| NCT00336557 |
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy |
https://ClinicalTrials.gov/show/NCT00336557 |
Completed |
Teva Pharmaceutical Industries |
2009-04-30 |
| NCT00325988 |
Biomarkers in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00325988 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00317564 |
Betaseron Pregnancy Registry |
https://ClinicalTrials.gov/show/NCT00317564 |
Completed |
Syneos Health |
2012-04-30 |
| NCT00321568 |
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00321568 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00288990 |
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00288990 |
Completed |
Biogen |
NA |
| NCT00262314 |
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT00262314 |
Completed |
EMD Serono |
2008-01-31 |
| NCT00238654 |
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy |
https://ClinicalTrials.gov/show/NCT00238654 |
Completed |
Teva Pharmaceutical Industries |
2008-07-31 |
| NCT00232193 |
Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS |
https://ClinicalTrials.gov/show/NCT00232193 |
Completed |
Providence Multiple Sclerosis Center |
2008-12-31 |
| NCT00229502 |
Cognitive Effects of Immunomodulatory Drugs in MS |
https://ClinicalTrials.gov/show/NCT00229502 |
Completed |
University of Kansas Medical Center |
2011-09-30 |
| NCT00223457 |
Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00223457 |
Completed |
University of Texas Southwestern Medical Center |
NA |
| NCT00206635 |
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00206635 |
Completed |
Bayer |
NA |
| NCT00203086 |
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00203086 |
Completed |
Teva Pharmaceutical Industries |
2009-10-31 |
| NCT00168714 |
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) |
https://ClinicalTrials.gov/show/NCT00168714 |
Completed |
Biogen |
2011-09-30 |
| NCT00099307 |
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00099307 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00094068 |
The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT00094068 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00819195 |
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00819195 |
Completed |
University of California, San Francisco |
2012-09-30 |
| NCT00819000 |
Therapy Optimization in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00819000 |
Completed |
Teva Pharmaceutical Industries |
2012-12-31 |
| NCT00064909 |
MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00064909 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00818038 |
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function |
https://ClinicalTrials.gov/show/NCT00818038 |
Completed |
Biogen |
2011-03-31 |
| NCT00001156 |
Assessment of Patients With Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00001156 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |